$Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy$

Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy

Bibliographic Details
Main Authors:	Selda Murat, Yüksel Çavuşoğlu, İlknur Ak Sivrikoz
Format:	Article
Language:	English
Published:	KARE Publishing 2021-10-01
Series:	Türk Kardiyoloji Derneği Arşivi
Online Access:	https://archivestsc.com/jvi.aspx?un=TKDA-09310&volume=49&issue=7

Similar Items

Cardiac scintigraphy-centered diagnostic process in transthyretin cardiac amyloidosis
by: Ilknur Ak Sivrikoz, et al.
Published: (2020-07-01)

Multimodality assessments of wild‐type transthyretin cardiac amyloidosis with no ventricular hypertrophy
by: Takuma Iwaya, et al.
Published: (2023-04-01)

Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study
by: Yüksel Çavuşoğlu, et al.
Published: (2024-01-01)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
by: Sebastiaan HC Klaassen, et al.
Published: (2020-08-01)

Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan
by: Takanori Naito, et al.
Published: (2023-06-01)

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction
by: Artem Ovchinnikov, et al.
Published: (2023-07-01)

Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score
by: Guglielmo Gioia, et al.
Published: (2024-08-01)

The Relationship Between Insulin Resistance Indicated by Triglyceride and Glucose Index and Left Ventricular Hypertrophy and Decreased Left Ventricular Diastolic Function with Preserved Ejection Fraction
by: Yang C, et al.
Published: (2024-06-01)

Epicardial Adipose Tissue and Left Ventricular Hypertrophy in Hypertensive Patients With Preserved Ejection Fraction: A Multicenter Retrospective Cohort Study
by: Runze Zhu, et al.
Published: (2025-01-01)

Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions
by: Se-Eun Kim, et al.
Published: (2024-10-01)

Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
by: Takuya Iino, et al.
Published: (2024-09-01)

Hyponatremia is associated with occurrence of atrial fibrillation in outpatients with heart failure and reduced ejection fraction
by: Yuksel Cavusoglu, et al.
Published: (2019-03-01)

FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction
by: Ture Lange Nielsen, et al.
Published: (2019-05-01)

Associations of Left Atrial Volume Index to Left Ventricular Ejection Fraction Ratio with Clinical Outcomes in Transthyretin Cardiac Amyloidosis
by: Yeabsra K. Aleligne, et al.
Published: (2024-11-01)

Cerebral Ischemic Events: An Overlooked Complication of Transthyretin Cardiac Amyloidosis in Afro-Caribbean Patients
by: Rishika Banydeen, et al.
Published: (2022-05-01)

Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis
by: Jan Malik, et al.
Published: (2023-06-01)

Importance of fourth heart sound and preserved left atrial function in wild‐type transthyretin amyloidosis
by: Yuri Ochi, et al.
Published: (2024-12-01)

Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2024-12-01)

FEATURES OF CEREBRAL HEMODYNAMICS AND MANIFESTATIONS OF HEPATIC ENCEPHALOPATHY IN CIRRHOSIS OF VIRAL ETIOLOGY AT DIFFERENT COMPENSATION STAGES WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
by: V. E. Kulikov, et al.
Published: (2017-09-01)

Left Ventricular Strain in Heart Failure with Preserved Ejection Fraction
by: Madhu Shukla, et al.
Published: (2023-01-01)

Association of renin–angiotensin–aldosterone system gene polymorphisms with left ventricular hypertrophy in patients with heart failure with preserved ejection fraction: A case–control study
by: Ehsan Bahramali, et al.
Published: (2017-05-01)

Right ventricular function and anemia in heart failure with preserved ejection fraction
by: Jia Wang, et al.
Published: (2024-11-01)

Physical activity and heart failure of preserved left ventricular ejection fraction
by: Mikić Lidija, et al.
Published: (2023-01-01)

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial
by: Morris M. Kim, et al.
Published: (2023-08-01)

Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
by: Vineet Agrawal, et al.
Published: (2019-12-01)

Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
by: Yuki Fujimura, et al.
Published: (2017-01-01)

Differential diagnosis of common etiologies of left ventricular hypertrophy using a hybrid CNN-LSTM model
by: In-Chang Hwang, et al.
Published: (2022-12-01)

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction
by: Ali Çoner, et al.
Published: (2021-09-01)

Right Ventricular Dimension for Heart Failure With Preserved Ejection Fraction Involving Right Ventricular-Vascular Uncoupling
by: Akito Nakagawa, MD, PhD, et al.
Published: (2022-11-01)

Cardiac amyloidosis – an underestimated etiology for heart failure with preserved ejection fraction. A literary review
by: R. Savova, et al.
Published: (2024-12-01)

Oral microbiota: An overlooked etiology for chemotherapy-induced oral mucositis?
by: Yan Wang, et al.
Published: (2015-04-01)

Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction
by: Martin Negreira-Caamaño, et al.
Published: (2023-02-01)

DIASTOLIC LEFT VENTRICULAR DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN ELDERLY
by: CALENICI Oleg, et al.
Published: (2022-04-01)

Sustained Ventricular Tachycardia as the first presentation of transthyretin amyloid cardiomyopathy
by: Hugo R. Ramos, et al.
Published: (2024-12-01)

Wild-type Transthyretin Amyloid Deposition in an Ascending Aortic Aneurysm
by: Abbas Hoteit, MD, et al.
Published: (2024-05-01)

Wild-Type Transthyretin Cardiac Amyloidosis in a Transplanted Heart
by: Lily K. Stern, MD, et al.
Published: (2023-08-01)

Negative bone scintigraphy in wild-type transthyretin cardiac amyloidosis
by: Nicolò Martini, et al.
Published: (2020-10-01)

Left ventricular hypertrophy: is it really?
by: Mikolich J, et al.
Published: (2013-01-01)

Moexipril and left ventricular hypertrophy
by: George S Chrysant, et al.
Published: (2007-03-01)

A rare presentation of multiple myeloma: Tc-99m MIBI SPECT imaging of orbital involvement
by: İlknur Ak Sivrikoz, et al.
Published: (2008-12-01)